Managing ARSACS: Treatment and Building Your Care Team
Published: | Updated:
While there is currently no cure for ARSACS, proactive management with a multidisciplinary care team can improve your quality of life and independence. Care focuses on treating symptoms like spasticity and coordination issues with medication and therapy, while promising gene therapies are researched.
Key Takeaways
- • Managing ARSACS requires a multidisciplinary medical team led by a neurologist to support physical, emotional, and social well-being.
- • Current standard of care is symptomatic, focusing on managing spasticity with medications like baclofen while balancing fall risks.
- • Physical and occupational therapy, including wheelchair skills training, are vital for maintaining mobility and daily independence.
- • Ophthalmologists monitor the condition using OCT scans to track changes in the retinal nerve fiber layer.
- • Emerging preclinical therapies, including mitochondrial support, Hsp90 inhibitors, and gene correction, are currently being researched.
Managing a rare condition like ARSACS requires more than just a single doctor; it requires a dedicated team of specialists who work together to support your physical, emotional, and social well-being. While there is currently no cure for ARSACS, proactive management can significantly improve your quality of life, maintain your independence for longer, and ensure you are ready for future treatments as they emerge from the lab [1][2].
Building Your Multidisciplinary Team
Because ARSACS affects several different systems in the body, your “care team” should ideally include specialists from various fields who communicate with one another [1][3].
- Neurologist: Usually the “captain” of the team, this specialist monitors the progression of the disease, interprets genetic results, and manages medications for symptoms [4].
- Physiatrist (Physical Medicine & Rehabilitation): A doctor who focuses on function and mobility. They are experts in managing spasticity (muscle stiffness) and can help determine when braces or other mobility aids are needed [2][3].
- Physical Therapist (PT): Essential for maintaining balance, strength, and coordination. They can also provide specialized manual wheelchair skills training to help you stay active and independent [5][6].
- Occupational Therapist (OT): Focuses on “activities of daily living,” such as writing, dressing, and using technology. They help you find ways to adapt your environment as hand coordination changes [7].
- Speech-Language Pathologist (SLP): ARSACS can affect the muscles used for speech and swallowing. Early work with an SLP can help manage dysarthria (speech difficulties) and ensure safe eating [8].
- Ophthalmologist: Performs the OCT scans needed to monitor changes in the retinal nerve fiber layer (RNFL), which is a key biomarker for the disease [9][10].
- Genetic Counselor: Helps explain the genetic risks for your siblings and future children, offering essential family planning guidance [11].
- Mental Health Professional: Navigating a progressive condition takes an emotional toll. A psychologist or medical social worker is vital for emotional support, developing coping strategies, and assisting with school or workplace accommodations.
Current Standard of Care: Managing Symptoms
Since there are no universal clinical guidelines yet, care is currently “symptomatic,” meaning it focuses on treating the specific challenges you face each day [1].
- Spasticity Management: Muscle stiffness in the legs is a core feature of ARSACS. Doctors may use medications like baclofen to help relax the muscles [3][2]. However, managing spasticity is a delicate balance. Sometimes, a certain amount of muscle stiffness is actually helping you support your weight and stand. Your doctor will carefully adjust medications so they don’t over-relax your muscles and accidentally unmask weakness or increase the risk of falls [2].
- Coordination Support: Tools like the LEMOCOT (Lower Extremity Motor Coordination Test) help your PT track how well your legs are coordinating so they can tailor your exercises to your specific needs [5].
- Functional Training: Research shows that intensive rehabilitation and wheelchair training can directly improve how patients move and interact with their communities [12][6].
Emerging Therapies: A Look Toward the Future
Scientists are working hard to move beyond managing symptoms to treating the root cause of ARSACS. Several promising areas are currently in the preclinical (tested in labs or animal models) phase:
- Mitochondrial Support (MitoQ): Because sacsin deficiency causes the cell’s “power plants” (mitochondria) to fail, researchers are testing MitoQ, an antioxidant that targets mitochondria. In lab models, it has shown promise in protecting Purkinje cells and improving coordination [13][14].
- Hsp90 Inhibitors: These are designed to help the cell deal with the “traffic jams” caused by vimentin bundling. By triggering the cell’s natural “heat-shock response,” these drugs may help clear out protein clumps and improve cell health [15][16].
- Gene Correction: Researchers are exploring ways to replace or fix the mutated SACS gene using advanced gene therapy techniques [17][18].
While these treatments are not yet available for general use, their progress in the lab provides a strong foundation for future human clinical trials. Staying connected with your care team and patient advocacy groups will ensure you are among the first to know when new research milestones are reached.
Frequently Asked Questions
Which doctors should be on my ARSACS care team?
How is muscle stiffness managed in ARSACS?
Why do I need to see an ophthalmologist for ARSACS?
Are there any new treatments or a cure for ARSACS?
Questions for Your Doctor
- • Are you familiar with the specific MRI and OCT hallmarks of ARSACS, such as pontine stripes and RNFL thickening?
- • How many other patients with ARSACS or early-onset hereditary ataxias do you currently manage?
- • Can you help coordinate my care with a physiatrist and a physical therapist who has experience with spastic ataxia?
- • What is your approach to managing spasticity when it begins to interfere with daily mobility?
- • Are you connected with any international ataxia research networks or foundations that can keep us informed about upcoming clinical trials?
- • How frequently should we be scheduling preventative physical therapy and occupational therapy evaluations?
Questions for You
- • Which of your current symptoms—balance, stiffness, or speech—is having the biggest impact on your daily life right now?
- • Do you feel that your current doctors listen to your concerns and explain things in a way you can understand?
- • How comfortable do you feel advocating for more specialized care or a second opinion if you feel your needs aren't being met?
- • What are your main goals for therapy (e.g., staying active in sports, improving handwriting, or walking more safely)?
Want personalized information?
Type your question below to get evidence-based answers tailored to your situation.
References
- 1
Expanding the clinical description of autosomal recessive spastic ataxia of Charlevoix-Saguenay.
Briand MM, Rodrigue X, Lessard I, et al.
Journal of the neurological sciences 2019; (400()):39-41 doi:10.1016/j.jns.2019.03.008.
PMID: 30901567 - 2
Functional mobility in walking adult population with ataxia of Charlevoix-Saguenay.
Lessard I, St-Gelais R, Hébert LJ, et al.
Orphanet journal of rare diseases 2021; (16(1)):432 doi:10.1186/s13023-021-02054-2.
PMID: 34649570 - 3
ARSACS: Clinical Features, Pathophysiology and iPS-Derived Models.
Salem IH, Blais M, Zuluaga-Sánchez VM, et al.
Cerebellum (London, England) 2025; (24(1)):24 doi:10.1007/s12311-024-01777-9.
PMID: 39753868 - 4
Journey Through Autosomal-Recessive Spastic Ataxia of Charlevoix-Saguenay: Insights From a Case Series of Seven Patients-A Single-Center Study and Review of an Indian Cohort.
Raval MA, Holla VV, Kamble N, et al.
Journal of movement disorders 2024; (17(4)):430-435 doi:10.14802/jmd.24154.
PMID: 39198013 - 5
Validity and reliability of the LEMOCOT in the adult ARSACS population: A measure of lower limb coordination.
Lessard I, Lavoie C, Côté I, et al.
Journal of the neurological sciences 2017; (377()):193-196 doi:10.1016/j.jns.2017.03.046.
PMID: 28477695 - 6
Efficacy of Manual Wheelchair Skills Training for Improving Skills and Confidence in People With Hereditary Degenerative Disorders: Protocol for a Sequential Multimethods Study.
Niyomwungere E, Routhier F, Gagnon C, et al.
JMIR research protocols 2025; (14()):e66974 doi:10.2196/66974.
PMID: 40742628 - 7
Wheelchair mobility, motor performance and participation of adult wheelchair users with ARSACS: a cross-sectional study.
Bourassa J, Routhier F, Gagnon C, et al.
Disability and rehabilitation. Assistive technology 2023; (18(4)):378-386 doi:10.1080/17483107.2020.1858195.
PMID: 33307884 - 8
Coordination and timing deficits in speech and swallowing in autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS).
Vogel AP, Rommel N, Oettinger A, et al.
Journal of neurology 2018; (265(9)):2060-2070 doi:10.1007/s00415-018-8950-4.
PMID: 29968200 - 9
Optical coherence tomography in autosomal recessive spastic ataxia of Charlevoix-Saguenay.
Parkinson MH, Bartmann AP, Clayton LMS, et al.
Brain : a journal of neurology 2018; (141(4)):989-999 doi:10.1093/brain/awy028.
PMID: 29538656 - 10
Retinal Architecture in Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS): Insights into Disease Pathogenesis and Biomarkers.
Rezende Filho FM, Bremner F, Pedroso JL, et al.
Movement disorders : official journal of the Movement Disorder Society 2021; (36(9)):2027-2035 doi:10.1002/mds.28612.
PMID: 33893680 - 11
Assessment of Sacsin Turnover in Patients With ARSACS: Implications for Molecular Diagnosis and Pathogenesis.
Longo F, De Ritis D, Miluzio A, et al.
Neurology 2021; (97(23)):e2315-e2327 doi:10.1212/WNL.0000000000012962.
PMID: 34649874 - 12
A rehabilitation program to increase balance and mobility in ataxia of Charlevoix-Saguenay: An exploratory study.
Lessard I, Masterman V, Côté I, et al.
PloS one 2022; (17(12)):e0279406 doi:10.1371/journal.pone.0279406.
PMID: 36576926 - 13
A mitochondrial-targeted antioxidant (MitoQ) improves motor coordination and reduces Purkinje cell death in a mouse model of ARSACS.
Márquez BT, Leung TCS, Hui J, et al.
Neurobiology of disease 2023; (183()):106157 doi:10.1016/j.nbd.2023.106157.
PMID: 37209925 - 14
Powerhouse failure and oxidative damage in autosomal recessive spastic ataxia of Charlevoix-Saguenay.
Criscuolo C, Procaccini C, Meschini MC, et al.
Journal of neurology 2015; (262(12)):2755-63 doi:10.1007/s00415-015-7911-4.
PMID: 26530509 - 15
Hsp90 Inhibition: A Promising Therapeutic Approach for ARSACS.
Nethisinghe S, Abeti R, Kesavan M, et al.
International journal of molecular sciences 2021; (22(21)) doi:10.3390/ijms222111722.
PMID: 34769152 - 16
Structures of ubiquitin-like (Ubl) and Hsp90-like domains of sacsin provide insight into pathological mutations.
Ménade M, Kozlov G, Trempe JF, et al.
The Journal of biological chemistry 2018; (293(33)):12832-12842 doi:10.1074/jbc.RA118.003939.
PMID: 29945973 - 17
Insights into SACS pathological attributes in autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS)☆.
Aly KA, Moutaoufik MT, Zilocchi M, et al.
Current opinion in chemical biology 2022; (71()):102211 doi:10.1016/j.cbpa.2022.102211.
PMID: 36126381 - 18
Short Review: Investigating ARSACS: models for understanding cerebellar degeneration.
Artero Castro A, Machuca C, Rodriguez Jimenez FJ, et al.
Neuropathology and applied neurobiology 2019; (45(6)):531-537 doi:10.1111/nan.12540.
PMID: 30636067
This page is for educational purposes only and does not replace professional medical advice. Always consult your neurologist and multidisciplinary care team regarding your specific ARSACS treatment plan.
Stay up to date
Get notified when new research about Autosomal recessive spastic ataxia of Charlevoix-Saguenay is published.
No spam. Unsubscribe anytime.